Jacobs Levy Equity Management
RCUS icon

Jacobs Levy Equity Management’s Arcus Biosciences RCUS Stock Holding History

Jacobs Levy Equity Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.3M Sell
430,346
-499,635
-54% -$10.8M 0.04% 317
2025
Q4 		$22.2M Sell
929,981
-190,081
-17% -$3.88M 0.09% 190
2025
Q3 		$15.2M Buy
1,120,062
+314,757
+39% +$3.27M 0.06% 238
2025
Q2 		$6.56M Sell
805,305
-166,852
-17% -$1.43M 0.03% 379
2025
Q1 		$7.63M Buy
972,157
+506,853
+109% +$5.88M 0.03% 382
2024
Q4 		$6.93M Buy
+465,304
New +$7.6M 0.02% 366
2024
Q3 		– Sell
-23,608
Closed -$360K – 1032
2024
Q2 		$360K Buy
+23,608
New +$381K ﹤0.01% 875
2024
Q1 		– Sell
-262,811
Closed -$5.02M – 1036
2023
Q4 		$5.02M Buy
262,811
+123,752
+89% +$1.98M 0.03% 425
2023
Q3 		$2.5M Buy
+139,059
New +$2.79M 0.01% 523
2020
Q2 		– Sell
-22,195
Closed -$308K – 1136
2020
Q1 		$308K Sell
22,195
-56,508
-72% -$703K ﹤0.01% 822
2019
Q4 		$795K Buy
78,703
+33,556
+74% +$282K 0.01% 725
2019
Q3 		$411K Buy
45,147
+27,071
+150% +$218K 0.01% 746
2019
Q2 		$144K Buy
+18,076
New +$181K ﹤0.01% 902

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Jacobs Levy Equity Management's RCUS Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Arcus Biosciences (RCUS) stake by 54% in Q1 2026, selling an estimated $10.8M and leaving 430,346 shares worth $9.3M. The position accounts for 0.04% of the portfolio, ranked #317.

Jacobs Levy Equity Management first reported a position in RCUS in Q2 2019 and has held it in 13 quarters since. The position peaked at $22.2M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Jacobs Levy Equity Management held 430,346 shares of Arcus Biosciences worth $9.3M as of Q1 2026.
  • Jacobs Levy Equity Management sold 499,635 Arcus Biosciences shares in Q1 2026, an estimated $10.8M.
  • Arcus Biosciences made up 0.04% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #317 holding.
  • Jacobs Levy Equity Management first reported a position in Arcus Biosciences in Q2 2019 and has held it in 13 quarters since.
  • Jacobs Levy Equity Management's Arcus Biosciences position peaked at $22.2M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.